摘要
目的探讨卡维地洛对扩张型心肌病心力衰竭的治疗作用。方法60例扩张型心肌病并发慢性心力衰竭患者随机分为治疗组和对照组各30例。对照组应用血管紧张肽转化酶抑制药(ACEI)、利尿药和洋地黄制剂,治疗组在对照组基础上加用卡维地洛,平均剂量为(28.66±12.48)mg.d-1,共治疗6个月,治疗前后采用超声心电图测定心功能进行疗效评价。结果治疗组治疗后左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)和左心室射血分数(LVEF)分别为(57.40±7.12)mm、(43.77±7.87)mm和(51.26±9.22)%,对照组分别为(63.08±7.03)mm、(52.24±7.85)mm和(42.38±7.45)%(P<0.01)。结论卡维地洛通过阻带β1,β2和α1受体,能明显改善心功能。
Objective To probe into the effect of carvedilol on the cardiac function in patients with dilated cardiomyopathy . Methods Sixty patients with dilated cardiomyopathy and chronic heart failure were randomly divided into two equal groups . Patients in the control group were treated with ACE inhibitor, diuretic and digoxin , while those in the treatment group were treated with carvedilol on the basis of above regular treatment, the average dose of carvedilol was （28.66 ±12.48） mg·d^-1. All the patients were observed for a total of six months . Before and after treatment the changes in cardiac function were evaluated by echocardiograph. Results After treatment, the left ventricular end-diastolic dimension（ LVEDD）, the left ventricular end-systolic dimension（LVESD） and the left ventricular ejection fraction（LVEF） in the treatment group were （57.40±7.12）mm, （43.77±7. 87）mm and （51. 26 ± 9. 22）%, respectively ,while those of the control group were （63.08 ±7.03） mm, （52.24±7.85） mm and （42.38±7.45）% ,respectively（P 〈0.01）. Conclusion Carvedilol can improve cardiac function significantly through the blockade of β1,β2 and α1receptors.
出处
《医药导报》
CAS
2006年第1期21-23,共3页
Herald of Medicine
关键词
卡维地洛
扩张型心肌病
心力衰竭
心功能
Carvedilol
Dilated cardiomyopathy
Heart failure
Cardiac function
